Happy Sunday to everyone on The Street — and, to those who celebrate, Happy Easter! 

American families might not be keeping up with the egg-dyeing tradition this year. In March, the average price of a dozen eggs hit a record high of $6.23.

Fortunately, some online influencers have a hack for that. Just dye potatoes instead!

Yeah, right. Cadbury $MDLZ ( ▲ 1.26% ) actually slashed the price of its classic chocolate eggs because not enough consumers were buying them. Traditional enough for me.

Jacob's Ladder

Analysts See Upside

Investors have shied away from stocks that could be impacted by federal government cuts and tariff tensions. That includes Jacobs Solutions $J ( ▲ 0.55% ) , which is down more than 12% this year.

However, a recent Barron's article argues this could be shortsighted. It points out that Jacobs Solutions actually spun off the majority of its government business last year. The company now relies on the US government for just 9% of its revenue.

In fact, Bryant VanCronkhite, co-manager of the Allspring Special Mid Cap Value fund, said Jacobs would have top-line growth "irrespective of the broader economy."

Plenty in the Pipeline

Analysts say one of the big pluses for Jacobs, which focuses on water projects, critical infrastructure, and life sciences services, is its solid pipeline of future projects. The company has nearly $22 billion worth of new projects in the offing.

Its efforts to streamline the business are also paying off. Not only does Jacobs have 25,000 projects globally, Barron’s argues, but those investments are flowing into sectors that look likely to grow.

For example, Jacobs Solutions specializes in advanced manufacturing projects. So, it may benefit from, say, pharmaceutical companies that produce obesity drugs or AI projects that rely on data centers.

Jacobs Solution Point

Jacobs isn't immune to economic shocks from federal funding cuts. About 60% of its revenue comes from the public sector, including state, local, and international governments. Plus, key clients may also be directly impacted by DOGE cutbacks.

Still, Citi rates it a Buy with a $160 price target. That's a 36% upside on last week’s close. According to the Wall Street Journal, 11 out of 19 analysts have Jacobs at a Buy or Overweight.

It remains to be seen whether Jacobs really can successfully engineer its way around the federal cuts, tariffs, and a potential recession. But right now, Barron's thinks this stock is a bargain.

Lockheed’s Lift-Off

Defense Goes Global

Lockheed Martin $LMT ( ▼ 2.73% ) just got a fresh stamp of approval from Morgan Stanley $MS ( ▲ 1.22% ) . The firm upgraded the defense giant to Overweight and raised its price target to $575 — good for nearly 24% upside from Friday’s close.

Analyst Kristine Liwag called Lockheed a “prime beneficiary” of rising international defense exports, with overseas contracts now making up almost 30% of its backlog.

Stand-Out Valuation

One key driver? Continued demand for the F-35. Despite some political noise — Canada has voiced hesitation — Liwag believes interest in the leading next-gen fighter aircraft isn’t fading anytime soon. She also believes the worst may be behind Lockheed when it comes to its Missiles and Fire Control segment.

Lockheed’s valuation is turning heads, too. Liwag pointed out that it trades at about a 10% discount to its Defense Prime peers, an attractive price point in the analyst’s eyes. If global defense spending keeps accelerating, Lockheed’s valuation can re-rate upwards, per Morgan Stanley.

Steady in a Storm

The Street isn’t unanimous. Of the 25 analysts covering LMT, 10 are bullish, while the rest are holding steady on the sidelines. But while the S&P 500 has stumbled this year, Lockheed has been quietly holding its ground. The stock is down just 4.5% year to date, compared to a 10% drop for the S&P 500.

Following Morgan Stanley’s upgrade, the stock saw a modest bump during the previous trading week. The positive rating comes at a time when investor interest in defense names has been elevated amid ongoing geopolitical tensions.

With Liwag highlighting both international momentum and an improving operational picture, Lockheed remains firmly on analysts’ radar heading deeper into 2025.

Together With RYSE

Apple's New Smart Display Confirms What This Startup Knew All Along

Apple has entered the smart home race with its new Smart Display, firing a $158B signal that connected homes are the future. 

When Apple moves in, it doesn’t just join the market — it transforms it.

One company has been quietly preparing for this moment. 

Their smart shade technology already works across every major platform, perfectly positioned to capture the wave of new consumers Apple will bring.

While others scramble to catch up, this startup is already shifting production from China to its new facility in the Philippines — built for speed and ready to meet surging demand as Apple’s marketing machine drives mass adoption.

With 200% year-over-year growth and distribution in over 120 Best Buy locations, this company isn’t just ready for Apple’s push — they’re set to thrive from it.

Shares in this tech company are open at just $1.90.

Apple’s move is accelerating the entire sector. Don’t miss this window.

The Spy Could Get Stuck In the Cold

Secret Service Scramble

Intelligence consulting firm Booz Allen Hamilton $BAH ( ▲ 2.15% ) relies on government contracts for 98% of its annual revenue. That puts it in a precarious position now that the Trump administration is making drastic cuts in federal spending.

Its stock has fallen around 30% since President Trump was elected. This week, analysts at JPMorgan Chase $JPM ( ▲ 1.02% ) , Truist $TFC ( ▼ 0.28% ) , and Bank of America $BAC ( ▲ 0.21% ) all reduced their BAH price targets. Goldman Sachs $GS ( ▲ 2.09% ) downgraded it from a Buy to Neutral.

Booz Allen Hamilton specializes in AI, cybersecurity, and quantum computing services. It has contracts with the intelligence community, the Department of Defense, NASA, and more.

BoozHound

The difficulty, as a recent WSJ article points out, is that Booz Allen's business is so cloak-and-dagger that investors can't judge just how precarious its position will be. A large proportion of its contracts are classified, which leaves investors in the dark.

However, we do know that the government plans to review over $65 billion in contracts that go to private companies, including some of Booz Allen's activities. Booz Allen has already put together proposals with over $1 billion in savings. Will it be enough?

Booz's Secret Weapon Could Backfire

Analysts are lukewarm on the stock. Per MarketWatch, 6 out of 15 have it at a Buy or Overweight. Just 1 says it's a Sell, but the remaining 8 have it as a Hold. 

Even the more optimistic analysts are revisiting their expectations. Bank of America analyst Mariana Perez Mora just cut her price target from $210 to $175 based on the shift in sentiment toward defense stocks. However, she maintained her Buy rating, and the price target still represents more than 50% upside from current prices. 

James Bond came back from the dead in You Only Live Twice. But this intelligence company will need more than a shaken martini to navigate the drastic federal contract cuts that are on the cards.

Last Week’s Poll Results

Are you bullish or bearish on gold over the next 12 months?

🟩🟩🟩🟩🟩🟩 🐂 Bullish

🟨🟨⬜️⬜️⬜️⬜️ 🐻 Bearish

• 🐂 Bullish —

  • “I see no impediment to gold rising, at this time. And any downward movement will be short-lived.”

  • “Now, but definitely not for the long term.”

• 🐻 Bearish —

  • “Unless war breaks out, not a lot more room to run.”

  • “The earlier rises defied market norms. How far can it go now? Then again, everyone is spooked!”

Are you bullish or bearish on McKesson (MCK) over the next 12 months?

🟩🟩🟩🟩🟩🟩 🐂 Bullish

🟨🟨🟨⬜️⬜️⬜️ 🐻 Bearish

And, in response, you said:

• 🐂 Bullish — “Very nice long-term chart; probably worthwhile to hold at least a small position.”

• 🐻 Bearish — “I am a cancer patient and am stuck relying on Biologics By McKesson for specialty medications. They have been an absolute NIGHTMARE to deal with! I sold every share I had in them about 6 months ago and would give every cent I own to my goldfish before ever owning another single share.”

This message includes a paid advertisement for RYSE Inc. The Street Sheet (SS) receives a flat fee from RYSE Inc totaling up to $7,500. Other than the compensation received for this advertisement sent to subscribers, The Street Sheet and its principals are not affiliated with RYSE Inc. This advertisement is sponsored by a third-party Reg A crowdfunding issuer and is for informational purposes only. The Street Sheet does not endorse or recommend any specific offering, and this advertisement should not be construed as a recommendation to invest. Investing in securities, including those offered through Reg A crowdfunding, involves risk, including the potential loss of principal. These investments are speculative, illiquid, and may involve a higher degree of risk compared to more traditional investments. The Street Sheet has not verified the information provided by the advertiser, and we encourage readers to conduct their own due diligence and consult with a licensed financial advisor or other qualified professional before making any investment decision. By engaging with this advertisement, you acknowledge that The Street Sheet and its affiliates are not responsible for any decisions or actions taken based on the information provided in this advertisement. All investments carry risks, and past performance is not indicative of future results. Readers should carefully review all information provided by the issuer, including the offering circular and any other available materials, prior to investing. The Street Sheet may receive compensation from the advertiser for promoting this offering. The Street Sheet and its principals do not own any of the stocks or shares mentioned in this email or in the article that this email links to. The Street Sheet is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information provided in this newsletter is not guaranteed as to accuracy or completeness. Each user of SS chooses to do trades at their sole discretion and risk. SS is not responsible for gains/losses that may result in the trading of these securities. This newsletter includes paid advertisements. The source of all third-party content in which SS receives some sort of compensation is clearly and prominently identified herein as "ad", "Sponsored", or “Together With”. Although we have sent you these advertisements, SS does not specifically endorse any third-party product nor is it responsible for the content, the accuracy, or the completeness of the advertisement or the experience with the third-party advertiser. Furthermore, we make no guarantee or warranty about what is in the advertisement. All investments involve risk, losses may exceed the principal invested, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. This communication from The Street Sheet is for informational purposes only. It is not intended to serve as a recommendation to buy, sell, or hold any security and is not an offer or sale of a security. Information contained within should not be perceived as a research report and is not intended to serve as the basis for any investment decision. Any third-party views reflected herein do not reflect the opinion of The Street Sheet. All investments involve risk and the past performance of a security does not guarantee future results or returns. There is always the potential for financial loss when investing in securities or other financial products. The information contained in this newsletter is subject to change without notice, and we do not undertake any obligation to update it. Readers are encouraged to conduct their own research and due diligence and seek advice from licensed professionals regarding their specific financial needs and circumstances. By reading this newsletter, you agree to hold us harmless from any and all losses, liabilities, costs, or expenses arising from your use or reliance on the information provided. There is no warranty as to the accuracy or completeness of the factual matters included in any advertisement or sponsored content in the newsletter. You have not performed any research on any entity, or its business, that advertises or submits any sponsored content. The Street Sheet is reader-supported. When you buy through links on our site, we may earn a commission.